In this regard, the detection of amyloid or tau pathology via fluid or neuroimaging biomarkers in non-demented individuals [in the cerebrospinal fluid (CSF), blood or positron-emission tomography (PET)] surpassing the pathological levels has been consistently associated with a higher risk of cognitive decline, MCI or dementia [7,8]. This evidence concerns the gene MAPT and amyloidosis.